Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures

  • Alexia Verroken,
  • Lydwine Defourny,
  • Olivier le Polain de Waroux,
  • Leïla Belkhir,
  • Pierre-François Laterre,
  • Michel Delmée,
  • Youri Glupczynski

There are numerical errors in the first and penultimate sentences of the second paragraph of the Results under the subheading “Rapid identification and susceptibility test performances.” The correct paragraph is: βLT performed on 164 BSI (P1 and P2 combined) yielded 24 positive, 139 negative and 1 uninterpretable test result due to an incoherent color change of the chromogenic test. All positive βLT results were found in non-natural AmpC EB isolates displaying third generation cephalosporin resistance by complete AST results and subsequently confirmed as ESBL producers. In 7 cases, βLT yielded false-negative results since complete AST and molecular testing identified 6 AmpC producing Escherichia coli and 1 VIM metallo-beta-lactamase-producing P. aeruginosa, all resistant to third generation cephalosporin. Globally, sensitivity and specificity of βLT were respectively 77.4% and 100%. No erroneous or uninterpretable results were observed with PBP2a testing. Performed on 25 S. aureus BSI in P1 and P2, PBP2a was able to detect all 3 MRSA strains (sensitivity and specificity of 100%). Ultimately, 8 BSI (6 in P1 and 2 in P2) were discarded from outcome analysis due to erroneous/uninterpretable rapid test results.

Tables 1 and 2 appear incorrectly in the published article. Please see the correct Tables 1 and 2 and their captions here.

thumbnail
Download:
Table 1. Distribution of microorganisms and main resistances of all bloodstream infections across the three study periods.

3GC, third generation cephalosporin (cefotaxime, ceftriaxone, ceftazidime); AST, antimicrobial susceptibility testing; BSI, bloodstream infection; carbapenem (imipenem, meropenem); ID, identification; P0, pre-intervention period; P1, intervention period 1; P2, intervention period 2. Natural AmpC producers identified during the study periods: Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Hafnia alvei, Serratia marcescens. Non-natural AmpC producers identified during the study periods: Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Salmonella spp.

https://doi.org/10.1371/journal.pone.0160537.t001

thumbnail
Download:
Table 2. Time to identification and time to partial/complete susceptibility results of all bloodstream infections during pre-intervention and intervention period 1 and 2.

https://doi.org/10.1371/journal.pone.0160537.t002

Reference

  1. 1. Verroken A, Defourny L, le Polain de Waroux O, Belkhir L, Laterre P-F, Delmée M, et al. (2016) Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures. PLoS ONE 11(5): e0156299. pmid:27228001

Citation: Verroken A, Defourny L, le Polain de Waroux O, Belkhir L, Laterre P-F, Delmée M, et al. (2016) Correction: Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures. PLoS ONE 11(9): e0160537. https://doi.org/10.1371/journal.pone.0160537

Published: September 22, 2016

Copyright: © 2016 Verroken et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.